Page last updated: 2024-10-15

9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine

Description

9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135436455
CHEMBL ID79979
SCHEMBL ID417577
MeSH IDM0147147

Synonyms (24)

Synonym
CHEMBL79979
2-(guanin-9-ylmethyl)-butan-1,4-diol
nsc-724807
nsc724807
(-/+)-2hm-hbg
(-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
2-amino-9-[4-hydroxy-2-(hydroxymethyl)butyl]-3h-purin-6-one
6h-purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-2-(hydroxymethyl)butyl)-, (+-)-
9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine
2hm-hbg
105868-85-7
h2g-homb
SCHEMBL417577
(-)-9-(4-hydroxy-2-hydroxymethylbutyl)guanine
(-)-9-(4hydroxy-2-hydroxymethylbutyl)guanine
9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
SCBFBAWJWLXVHS-UHFFFAOYSA-N
9-(4-hydroxy-2-hydroxymethylbutyl)guanine
2-amino-9-[4-hydroxy-2-(hydroxymethyl)butyl]-6,9-dihydro-1h-purin-6-one
(rs)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
2-amino-9-(4-hydroxy-2-(hydroxymethyl)butyl)-1h-purin-6(9h)-one
2-amino-9-[4-hydroxy-2-(hydroxymethyl)butyl]-1h-purin-6-one
2-amino-9-[4-hydroxy-2-(hydroxymethyl)butyl]-3,9-dihydro-6h-purin-6-one
DTXSID20869696

Pharmacokinetics

ExcerptReference
" This report is concerned with the pharmacokinetic evaluation of the drug in rats and monkeys and its antiviral activity in African green monkeys infected with simian varicella virus (SVV), a virus closely related to varicella-zoster virus that is also susceptible to inhibition by (+/-)2HM-HBG."( Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.
Abele, G; Datema, R; Lake-Bakaar, DM; Lindborg, B; Soike, KF, 1988
)

Bioavailability

ExcerptReference
" The sodium or hydrochloride salts and short-chain esters of (+/-)2HM-HBG showed bioavailability characteristics that were equally as poor as those of (+/-)2HM-HBG."( Improvement of the absorption of oral (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, an anti-varicella-zoster virus drug, in rats and monkeys.
Datema, R; Lake-Bakaar, DM; Lindborg, B, 1989
)
"4 h, and an oral bioavailability of 10."( Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.
Abele, G; Datema, R; Lake-Bakaar, DM; Lindborg, B; Soike, KF, 1988
)

Dosage Studied

ExcerptReference
" (+/-)2HM-HBG at a dosage of 10 mg/kg of body weight per day allowed moderate viremia, whereas a dosage of 30 mg/kg of body weight per day strongly suppressed viremia with minimal numbers of virus plaques from blood specimens collected at days 3, 5, and 7 postinfection and complete clearance at day 9 postinfection."( Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.
Abele, G; Datema, R; Lake-Bakaar, DM; Lindborg, B; Soike, KF, 1988
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID82116Antiviral activity against HIV-1 was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID90940Antiviral activity against HCMV was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (25.00)18.7374
1990's5 (41.67)18.2507
2000's4 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]